Literature DB >> 15073801

Reasons for reporting adverse drug reactions--some thoughts based on an international review.

C Biriell1, I R Edwards.   

Abstract

A pilot study was made to explore positive reasons for physicians and pharmacists taking time to report adverse reactions, rather than reasons for failing to report which has been studied by many authors. The 34 national drug monitoring centres participating in the international programme at the time of the study were asked by letter from the WHO Collaborating Centre for International Drug Monitoring, Uppsala to investigate the reasons why adverse reactions were reported. National Centres were asked to write to 20 consecutive reporters, sending each a copy of their own report, asking why they had chosen to report that particular reaction, and asking for more general comment. Twelve countries responded with information about the habits and views of the reporters of 177 cases. Since this was an explorative pilot study the letter to reporters deliberately had only an open question about reason for reporting. Categories were developed by the WHO Centre from the responses given. Reasons for reporting fell into a total of 14 categories with the great majority in the top six: motivation to contribute to medical knowledge, reaction previously unknown to reporter, reaction to new drug, all significant reactions reported, known association between drug and reaction, and severity of reaction. Copyright 1997 by John Wiley & Sons, Ltd.

Year:  1997        PMID: 15073801     DOI: 10.1002/(SICI)1099-1557(199701)6:1<21::AID-PDS259>3.0.CO;2-I

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  25 in total

1.  Spontaneous reporting--of what? Clinical concerns about drugs.

Authors:  I R Edwards
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

Review 2.  Application of data mining techniques in pharmacovigilance.

Authors:  Andrew M Wilson; Lehana Thabane; Anne Holbrook
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

3.  Pharmacovigilance among surgeons and in surgical wards: overlooked or axiomatic?

Authors:  Gabriel Sunil Rodrigues; Sohil Ahmed Khan
Journal:  Indian J Surg       Date:  2010-12-01       Impact factor: 0.656

4.  Expectations for feedback in adverse drug reporting by healthcare professionals in the Netherlands.

Authors:  Ingrid Oosterhuis; Florence P A M van Hunsel; Eugène P van Puijenbroek
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

5.  Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.

Authors:  Paul Gavaza; Carolyn M Brown; Star Khoza
Journal:  Pharm World Sci       Date:  2010-07-23

6.  Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital.

Authors:  A Vallano; G Cereza; C Pedròs; A Agustí; I Danés; C Aguilera; J M Arnau
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

7.  Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; Juan Jesus Gestal-Otero
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.

Authors:  Claire Anderson; Janet Krska; Elizabeth Murphy; Anthony Avery
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

9.  Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada.

Authors:  Vincent Nichols; Isabelle Thériault-Dubé; Julie Touzin; Jean-François Delisle; Denis Lebel; Jean-François Bussières; Benoît Bailey; Johanne Collin
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.

Authors:  Yanqing Ji; Hao Ying; Margo S Farber; John Yen; Peter Dews; Richard E Miller; R Michael Massanari
Journal:  IEEE Trans Inf Technol Biomed       Date:  2009-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.